Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the target of a large increase in short interest in November. As of November 15th, there was short interest totalling 6,910,000 shares, an increase of 29.2% from the October 31st total of 5,350,000 shares. Based on an average daily volume of 1,460,000 shares, the short-interest ratio is presently 4.7 days.

Institutional Trading of Adaptimmune Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC boosted its stake in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after acquiring an additional 21,769 shares during the last quarter. Jane Street Group LLC increased its position in Adaptimmune Therapeutics by 130.4% in the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after buying an additional 98,581 shares in the last quarter. FMR LLC raised its stake in shares of Adaptimmune Therapeutics by 3.0% in the third quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after buying an additional 50,419 shares during the period. Baillie Gifford & Co. lifted its position in shares of Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after buying an additional 1,626,657 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at about $95,000. 31.37% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Trading Down 0.6 %

Adaptimmune Therapeutics stock opened at $0.72 on Friday. Adaptimmune Therapeutics has a 52-week low of $0.43 and a 52-week high of $2.05. The company has a market cap of $184.41 million, a P/E ratio of -3.30 and a beta of 2.26. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.62. The business has a 50-day simple moving average of $0.81 and a two-hundred day simple moving average of $1.00.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ADAP. Guggenheim lowered their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, November 15th. HC Wainwright lowered their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating on the stock in a research note on Thursday, November 14th. Mizuho reduced their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday. Finally, StockNews.com downgraded shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $2.79.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.